- New drug Zanubrutinib reduces tumor size in 80% of lymphoma patients
- Study shows robotic surgery is safer and reduces patient recovery time by 20%
- What is the relationship between Harmful metabolites of TME and antitumor immunity?
- What we should know and reflect on Monkeypox outbreak?
- Nucleic acid drugs can achieve functional cure of hepatitis B
- Scientists find effects of COVID-19 infection on thyroid can last at least a year
CAR-T therapy treats ovarian cancer
CAR-T therapy treats ovarian cancer.
CAR-T therapy treats ovarian cancer. Among gynecological malignancies, ovarian cancer is called the “silent killer”. Although the incidence rate is lower than that of cervical cancer and endometrial cancer, only 20% of patients are diagnosed at an early stage because the symptoms are hidden.
Most patients are already in the middle and late stages when they are diagnosed. They have lost the opportunity for surgical treatment and can only choose chemotherapy, radiotherapy, etc.
The clinical effect is not satisfactory. The 5-year survival rate is the lowest among gynecological tumors, only 39%, and new treatment methods are urgently needed.
In the past two years, the advent of CAR-T therapy has allowed people to see the hope of “cure” cancer.
The three CAR-T therapies approved by the FDA have shown amazing efficacy in hematological tumors, with an overall remission rate of 80%. % Above, the complete remission rate also exceeds 50%!
Researchers hope that CAR-T therapy can also exert a strong anti-cancer effect in ovarian cancer.
The dawn of CAR-T therapy for ovarian cancer is beginning!
At present, with the change of CAR-T technology, this therapy has finally broken the ice in the field of solid tumors. More and more clinical trials have begun to try to use CAR-T for the treatment of ovarian cancer, and a major breakthrough has been made!
1. The new CAR-T targeting FSH is expected to be tested in humans
A team of researchers led by Dr. Jose R. Conejo-Garcia, head of the Department of Immunology at Moffitt Cancer Center, developed a CAR that introduces Follicle Stimulating Hormone (FSH) into T cells.
The new genetically modified CAR T cells can accurately find and destroy cancer cells that express the FSH receptor protein found in a large number of ovarian cancer cells. At present, this new type of CAR-T therapy is submitting a “new drug research” application to the FDA for human clinical trials. If approved, clinical trials are expected to start in 2021.
2. The new CAR-T completely eliminates cancer cells in mice with ovarian cancer
In addition, a clinical trial of a new generation of chimeric ovarian cancer antigen receptor T (CAR-T) cell therapy has attracted the attention of the medical community.
Preclinical research results of this new type of CAR-T show that it can completely eliminate cancer cells in mouse models of ovarian cancer, and it is currently preparing to apply for clinical trials in humans.
(source:internet, reference only)